Clinical Study
Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
Table 1
Epidemiological, clinical, and biological features of patients.
| | Variables | Numbers (%) |
| | Age (years) mean age 38 years (13–68) | | | 11–30 | 13 (48) | | 31–50 | 9 (33) | | 51–70 | 5 (19) | | Sex | | | Male | 18 (67) | | Female | 9 (33) | | Socioeconomic level | | | Low | 10 (37) | | Average | 17 (63) | | Reason for consultation | | | Hyperleukocytosis | 17 (63) | | Hyperleukocytosis + splenomegaly | 10 (37) | | Performance status | | | 0 and 1 | 0 (0) | | 2 and 3 | 13 (48) | | 4 | 14 (52) | | Bone pains | | | Presence | 13 (48) | | Fever | | | Presence | 20 (74) | | Hepatomegaly | | | Presence | 13 (48) | | Lymphadenopathy | | | Presence | 6 (22) | | Splenomegaly | | | 0 cm | 0 (0) | | 1–9 cm | 7 (26) | | ≥10 cm | 7 (26) | | Hemogram (median values and extremes) | | | White Blood Cells (109/L) | 341.2 (140–650) | | Hemoglobin (g/dL) | 8.5 (5.7–12.4) | | Platelets (109/L) | 340 (57–1992) | | Polynuclear basophiles (%) | 5 (0–9) | | Blasts (%) | 7 (0–16) | | Promyelocytes (%) | 8 (0–18) | | Sokal score | | | Low | 0 (0) | | Intermediate | 9 (33) | | High | 18 (67) |
|
|
